Oncology Institute And 2 Other Promising Penny Stocks To Watch

Over the last 7 days, the United States market has risen by 2.9%, and over the past year, it is up 12%, reflecting a period of growth and optimism. In such a climate, identifying stocks with solid financials and growth potential becomes crucial for investors seeking value. While penny stocks may seem like a term from another era, they continue to represent opportunities in smaller or emerging companies that can offer both affordability and potential upside when chosen wisely.

Top 10 Penny Stocks In The United States

Click here to see the full list of 723 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Oncology Institute (NasdaqCM:TOI)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: The Oncology Institute, Inc. is a U.S.-based company offering a range of medical oncology services with a market cap of $226.50 million.

Operations: Revenue Segments: No specific revenue segments are reported for this U.S.-based company providing medical oncology services.

Market Cap: $226.5M

The Oncology Institute, Inc. is navigating the challenges typical of penny stocks, with high volatility and significant debt levels—a net debt to equity ratio of 673.8%. Despite being unprofitable and not expected to achieve profitability in the next three years, its revenue is projected to grow by 15.87% annually. Recent developments include reaffirmed revenue guidance for 2025 between US$460 million and US$480 million, strategic partnerships enhancing clinical research access, and a shelf registration filing for US$76.79 million in common stock offerings. The company has also launched initiatives like the Florida Oncology Network to expand its care footprint.

• Unlock comprehensive insights into our analysis of Oncology Institute stock in this financial health report.
• Gain insights into Oncology Institute's future direction by reviewing our growth report.

Ardelyx (NasdaqGM:ARDX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Ardelyx, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines for unmet medical needs globally, with a market cap of approximately $928.31 million.

Operations: The company generates revenue primarily from the development and commercialization of biopharmaceutical products, amounting to $361.71 million.

Market Cap: $928.31M

Ardelyx, Inc. is experiencing the volatility typical of penny stocks, with a focus on developing innovative treatments like IBSRELA and XPHOZAH. Despite being currently unprofitable with a negative return on equity of -36.91%, the company has shown promising revenue growth, reporting US$74.11 million in Q1 2025 compared to US$46.02 million a year ago. Ardelyx's short-term assets significantly exceed its liabilities, providing some financial stability amidst high debt levels that have increased over five years. Recent board appointments and product announcements highlight strategic efforts to strengthen its market position in biopharmaceuticals for unmet medical needs.

• Click here to discover the nuances of Ardelyx with our detailed analytical financial health report.
• Understand Ardelyx's earnings outlook by examining our growth report.

Clover Health Investments (NasdaqGS:CLOV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Clover Health Investments, Corp. offers Medicare Advantage plans in the United States and has a market cap of approximately $1.80 billion.

Operations: The company generates revenue primarily through its Insurance segment, which accounted for $1.49 billion.

Market Cap: $1.8B

Clover Health Investments is navigating the penny stock landscape with a focus on Medicare Advantage plans, reporting a reduced net loss of US$1.27 million in Q1 2025 from US$19.17 million a year ago. Despite being unprofitable and having a negative return on equity, it remains debt-free and its short-term assets cover both short- and long-term liabilities, providing some financial cushion. Recent leadership changes include the appointment of Dr. Shelly Gupta as Chief Medical Officer to enhance clinical operations and patient access initiatives, while significant insider selling may raise concerns among investors about internal confidence levels.

• Navigate through the intricacies of Clover Health Investments with our comprehensive balance sheet health report here.
• Review our growth performance report to gain insights into Clover Health Investments' future.

Taking Advantage

• Reveal the 723 hidden gems among our US Penny Stocks screener with a single click here.
• Curious About Other Options? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 28 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com